.png){kind=icon}
返回
Pemafibrate: First Global Approval
.png){kind=icon}
PRE
AI
DOI：10.1007/s40265-017-0818-x.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Pemafibrate (Parmodia (R)) is a novel, highly selective peroxisome proliferator-activated receptor (PPAR)-alpha modulator (SPPARM). It acts by binding to PPAR-alpha and regulating the expression of target genes that modulate lipid metabolism, thereby decreasing plasma triglyceride levels and increasing high-density lipoprotein cholesterol levels. Developed by Kowa Company, Ltd., oral pemafibrate has been approved in Japan for the treatment of hyperlipidaemia (including familial hyperlipidaemia). This article summarizes the milestones in the development of pemafibrate leading to this first global approval for hyperlipidaemia.
Keyword:
PPAR-ALPHA MODULATOR
SPPARM-ALPHA
DYSLIPIDEMIC PATIENTS
DOUBLE-BLIND
K-877
HYPERLIPIDEMIA
POTENT
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
引用论文
The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.png)
ATHEROSCLEROSIS
ATHEROSCLEROSISIF5.7
PREAI
分享收藏Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trialATHEROSCLEROSIS
OAAI
ATHEROSCLEROSISIF5.7
OAAI分享收藏Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice选择性过氧化物酶体增殖物激活受体-α 调节剂K-877有效激活过氧化物酶体增殖物激活受体-α 途径并改善小鼠脂质代谢OAAI
OAAI分享收藏Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemiaATHEROSCLEROSISOAAI
ATHEROSCLEROSISIF5.7
OAAI分享收藏Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice新型选择性ppar α 调节剂K-877对小肠的影响有助于改善低密度脂蛋白受体基因敲除小鼠的高脂血症OAAI
OAAI分享收藏 没有更多内容
没有更多内容